Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
104
-
Total 13F shares, excl. options
-
54.2M
-
Shares change
-
+466K
-
Total reported value, excl. options
-
$235M
-
Value change
-
-$5.21M
-
Put/Call ratio
-
1.38
-
Number of buys
-
41
-
Number of sells
-
-66
-
Price
-
$4.33
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q4 2021
133 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q4 2021.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 104 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.2M shares
of 166M outstanding shares and own 32.77% of the company stock.
Largest 10 shareholders include Point72 Asset Management, L.P. (6.3M shares), RTW INVESTMENTS, LP (6.03M shares), BVF INC/IL (5.8M shares), VANGUARD GROUP INC (5.11M shares), BlackRock Inc. (4.96M shares), ORBIMED ADVISORS LLC (3.21M shares), STATE STREET CORP (2.74M shares), Rubric Capital Management LP (2.41M shares), Candriam Luxembourg S.C.A. (1.76M shares), and MILLENNIUM MANAGEMENT LLC (1.27M shares).
This table shows the top 104 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.